RedHill Biopharma (NASDAQ:RDHL) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research report issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

RedHill Biopharma Stock Down 3.5 %

Shares of RDHL opened at $6.67 on Tuesday. The stock has a fifty day simple moving average of $7.48 and a two-hundred day simple moving average of $86.34. The company has a market capitalization of $8.54 million, a PE ratio of -0.67 and a beta of 3.65. RedHill Biopharma has a 52-week low of $6.00 and a 52-week high of $38.50.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.